Meet us next:   BIO International Convention 2025 – 16-19 June 2025  ●  more on our events calendar

Clinical Stem Cell Services

Histocell – our GMP iPSC and MSC Manufacturing Partner in Europe

histocell-spain

Located in Bilbao, Spain, Histocell is a CDMO and a clinical-stage biopharmaceutical company that specializes in developing cell therapy products for regenerative medicine.

Histocell's highly reliable and qualified scientific team has more than 20 years of experience. They will take care of your iPSC or MSC cell therapy needs with a flexible and scalable manufacturing process.

In our GMP stem cell services partnership:

  • Histocell manufactures investigational medicinal products for human use for European, US, and Japanese customers.
  • Histocell also provides all regulatory safety and quality controls specified by regulatory authorities and all additional required documentary support for the cells.

Histocell-lab-1

Authorized GMP facility for Manufacturing Clinical Grade Products

Histocell's newly built 600 m2 GMP facility is already authorized and registered by the European Union Manufacturer Authorization (EMA) for the manufacturing of clinical grade cells in compliance with the GMP guidelines of EMA Regulation (EU) 2017/1569.

histocell-cdmo-cell-therapy-22-1

Advanced Therapy Medicinal Products (ATMPs) Manufacturing

Since 2011, Histocell has been an authorized provider of GMP ATMPs manufacturing services to clients around the world.

Around 300 patients have already been treated with ATMPs manufactured by Histocell, and more than 350 batches have been manufactured under GMP.

histocell labs corridor

Advanced Therapy Cell Production Facilities

Histocell's new Advanced Therapies GMP cell production unit has more than 600 m2 of capacity.

  • GMP manufacturing suites and associated infrastructure
  • Fully equipped to manufacture both autologous and allogeneic therapies
  • Manufacturing and storage for cell therapy stocks (MCB, WCB)
  • Production and characterization of cell-derived biologics such as secretomes and exosomes
  • Manufacturing capability: approx. 1200 batches/year
  • Designed to support both pre-clinical and clinical phases
  • Histocell is also gearing up to support commercial manufacturing 

Services We Offer In Partnership With Histocell

Working together, REPROCELL and Histocell are well placed to support your GMP stem cell manufacturing project.

Ask our experts about our GMP services

Discover more

Clinical Stem Cell Services

Resources

Gene Editing Services

Resources

Research Stem Cell Services

Resources

On the REPROCELL blog

Latest in Stem Cells

Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed

Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed

Overcome key challenges in clinical iPSC applications with REPROCELL's ethical sourcing, advanced reprogramming, and tailored solutions for reliable, scalable therapies.

12 May 2025

Epigenetic Modifications: Their Role in iPSC Reprogramming and Differentiation

Epigenetic Modifications: Their Role in iPSC Reprogramming and Differentiation

Explore the critical role of epigenetic mechanisms like DNA methylation and histone modifications in iPSC reprogramming and differentiation. Learn how optimizing epigenetic stability enhances reprogramming efficiency, reduces variability, and ensures safer, more reliable iPSC applications for research and therapy.

02 May 2025

REPROCELL Connects with Maryland Governor Moore During His Japan Visit

REPROCELL Connects with Maryland Governor Moore During His Japan Visit

Maryland Governor Moore strengthens biotech ties with Japan, highlighting REPROCELL's pivotal role in the Maryland-Kanagawa partnership during his trade mission.

22 April 2025

Exosomes from Stem Cells: iPSC vs. MSC-Derived Exosomes for Aesthetic and Regenerative Medicine

Exosomes from Stem Cells: iPSC vs. MSC-Derived Exosomes for Aesthetic and Regenerative Medicine

Discover how iPSC and MSC-derived exosomes revolutionize skin rejuvenation and anti-aging treatments in aesthetic medicine. Main Point Summary: The blog explores the potential of exosomes derived from induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) for skin rejuvenation and anti-aging treatments in aesthetic medicine, comparing their effectiveness, mechanisms, and applications.

14 April 2025

More in Stem Cells